TiumBio Co., Ltd. (KOSDAQ:321550)
South Korea · Delayed Price · Currency is KRW 7,650.00
+500.00 (6.99%)
At close: Mar 13, 2026
TiumBio Revenue
TiumBio had revenue of 3.12B KRW in the quarter ending September 30, 2025, with 175.77% growth. This brings the company's revenue in the last twelve months to 9.32B, up 21.54% year-over-year. In the year 2024, TiumBio had annual revenue of 6.79B with 38.65% growth.
Revenue (ttm)
9.32B
Revenue Growth
+21.54%
P/S Ratio
23.86
Revenue / Employee
n/a
Employees
n/a
Market Cap
222.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.79B | 1.89B | 38.65% |
| Dec 31, 2023 | 4.90B | -4.22B | -46.27% |
| Dec 31, 2022 | 9.12B | 9.06B | 15,952.75% |
| Dec 31, 2021 | 56.80M | -992.15M | -94.59% |
| Dec 31, 2020 | 1.05B | -64.05M | -5.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ISU Abxis | 66.39B |
| NIBEC | 32.96B |
| Genome & Company | 25.95B |
| Prestige Biologics | 19.24B |
| QuadMedicine | 13.11B |
| Kangstem Biotech | 12.77B |
| Bio Solution | 8.27B |
| curacle co.,ltd. | 1.14B |